Veterinary pharmaceuticals manufacturer Norbrook Laboratories Ltd has added to its small animal range with the launch of Propentofylline tablets, for the treatment of a range of ailments in ageing dogs.
Veterinary pharmaceuticals manufacturer Norbrook Laboratories Ltd has added to its small animal range with the launch of Propentofylline, for the treatment of a range of ailments in ageing dogs.
Available in 50mg and 100mg tablets, Propentofylline can be prescribed to help boost a dog’s willingness to exercise and improve exercise tolerance.
Michelle Jones, brand manager, small animal, said: “We launched Propentofylline to the UK market at the recent VPMA Congress where it was warmly received by the delegates with plenty of positive comments on both the lively design of the campaign and the opportunities for use of this product in practice.
“The product is indicated for improving dullness, lethargy and general demeanour in dogs to essentially give them a new lease of life.”
Propentofylline tablets are now available to UK veterinary practices, backed by a range of promotional support materials – including a technical brochure and waiting room posters. Practices can also take advantage of an introductory offer, which Norbrook territory managers will be discussing with their clients.
Speaking at the launch, VPMA president Pauline Graham said: “Propentofylline, as an active ingredient, is widely prescribed by vets with its properties that assist increased blood flow, particularly to the heart and skeletal muscle. Also increasing the blood flow to the brain and therefore its oxygen supply, it is a well recognised treatment for older, lethargic dogs to help encourage brightness as well as tolerance and willingness to exercise.
“I am pleased to see Norbrook offering this product as another high quality and cost effective addition to their small animal range,” she added.